{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:17:06Z","timestamp":1791472626245,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KI1006I"],"award-info":[{"award-number":["01KI1006I"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.antiviral.2013.03.006","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T23:30:47Z","timestamp":1363735847000},"page":"319-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro"],"prefix":"10.1016","volume":"98","author":[{"given":"Emanuel","family":"Haasbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Hartmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Planz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.03.006_b0005","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.bmcl.2008.10.054","article-title":"The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901","volume":"18","author":"Barrett","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.03.006_b0010","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2165\/11537960-000000000-00000","article-title":"Drugs in development for influenza","volume":"70","author":"Boltz","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2013.03.006_b0015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou\u2013Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2013.03.006_b0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","article-title":"Antiviral activity of the MEK inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo","volume":"92","author":"Droebner","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.006_b0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-8722-3-8","article-title":"From basic research to clinical development of MEK1\/2 inhibitors for cancer therapy","volume":"3","author":"Fremin","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.antiviral.2013.03.006_b0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.006_b0035","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.antiviral.2011.07.006","article-title":"Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses","volume":"91","author":"Haasbach","year":"2011","journal-title":"Antiviral Res."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.03.006_b0040","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold?","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.006_b0045","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-09-0679","article-title":"RDEA119\/BAY 869766: a potent, selective, allosteric inhibitor of MEK1\/2 for the treatment of cancer","volume":"69","author":"Iverson","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2013.03.006_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkp161","article-title":"Targeting cell signaling pathways to fight the flu: towards a paradigm change in anti-influenza therapy","volume":"64","author":"Ludwig","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.006_b0055","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1515\/BC.2011.121","article-title":"Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections","volume":"392","author":"Ludwig","year":"2011","journal-title":"Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.006_b0060","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1515\/BC.2008.148","article-title":"Influenza viruses and the NF-kappaB signaling pathway-towards a novel concept of antiviral therapy","volume":"389","author":"Ludwig","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.006_b0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2011.05.009","article-title":"Inhibition of influenza virus-induced NF-kappaB and Raf\/MEK\/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo","volume":"92","author":"Pinto","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.006_b0070","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1128\/JVI.75.10.4871-4877.2001","article-title":"MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells","volume":"75","author":"Planz","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.006_b0075","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1515\/BC.2008.145","article-title":"RNA viruses and the mitogenic Raf\/MEK\/ERK signal transduction cascade","volume":"389","author":"Pleschka","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.006_b0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/35060098","article-title":"Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signaling cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.antiviral.2013.03.006_b0085","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2174\/1381612043384439","article-title":"MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors","volume":"10","author":"Sebolt-Leopold","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.antiviral.2013.03.006_b0090","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.antiviral.2013.03.006_b0095","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.006_b0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.006_b0105","unstructured":"Wallace, E.M., Lyssikatos, J., Blake, J.F., Marlow, A., Greschuk, J., Yeh, T.C., Callejo, M., Marsh, V., Poch, G., Winkler, J.J., Koch, K., Davies, B.R., Wilkinson, R.W., Jones, D.C., Logie, A., McKay, J., Smith, P.D., Robinson, D.T., 2009. AZD8330 (ARRY-424704): preclinical evaluation of a potent, selective MEK 1\/2 inhibitor currently in phase I trails. AACR 100th Annual Meeting. Denver, USA, 18th \u201322nd April."},{"key":"10.1016\/j.antiviral.2013.03.006_b0110","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin. Cancer Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:25:55Z","timestamp":1759062355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0166354213000600"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}